nodes	percent_of_prediction	percent_of_DWPC	metapath
Nepafenac—PTGS1—Ifosfamide—testicular cancer	0.38	0.382	CbGbCtD
Nepafenac—PTGS2—Cisplatin—testicular cancer	0.219	0.22	CbGbCtD
Nepafenac—PTGS2—Etoposide—testicular cancer	0.215	0.216	CbGbCtD
Nepafenac—PTGS1—Etoposide—testicular cancer	0.182	0.182	CbGbCtD
Nepafenac—Ocular discomfort—Methotrexate—testicular cancer	0.000201	0.052	CcSEcCtD
Nepafenac—Dermatitis atopic—Chlorambucil—testicular cancer	0.000197	0.051	CcSEcCtD
Nepafenac—Photophobia—Vinblastine—testicular cancer	0.000126	0.0325	CcSEcCtD
Nepafenac—Eye irritation—Ifosfamide—testicular cancer	0.000113	0.0292	CcSEcCtD
Nepafenac—Impaired healing—Methotrexate—testicular cancer	0.000106	0.0273	CcSEcCtD
Nepafenac—Arthritis—Bleomycin—testicular cancer	8.44e-05	0.0218	CcSEcCtD
Nepafenac—Lacrimation—Epirubicin—testicular cancer	7.27e-05	0.0188	CcSEcCtD
Nepafenac—Lacrimation—Doxorubicin—testicular cancer	6.73e-05	0.0174	CcSEcCtD
Nepafenac—Keratitis—Epirubicin—testicular cancer	6.59e-05	0.017	CcSEcCtD
Nepafenac—Keratitis—Doxorubicin—testicular cancer	6.1e-05	0.0158	CcSEcCtD
Nepafenac—Dermatitis atopic—Epirubicin—testicular cancer	5.77e-05	0.0149	CcSEcCtD
Nepafenac—Dermatitis atopic—Doxorubicin—testicular cancer	5.34e-05	0.0138	CcSEcCtD
Nepafenac—Hypertension—Vinblastine—testicular cancer	5.05e-05	0.0131	CcSEcCtD
Nepafenac—Lacrimation increased—Epirubicin—testicular cancer	4.64e-05	0.012	CcSEcCtD
Nepafenac—Eye disorder—Ifosfamide—testicular cancer	4.53e-05	0.0117	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Chlorambucil—testicular cancer	4.5e-05	0.0116	CcSEcCtD
Nepafenac—Angiopathy—Ifosfamide—testicular cancer	4.4e-05	0.0114	CcSEcCtD
Nepafenac—Immune system disorder—Ifosfamide—testicular cancer	4.38e-05	0.0113	CcSEcCtD
Nepafenac—Lacrimation increased—Doxorubicin—testicular cancer	4.29e-05	0.0111	CcSEcCtD
Nepafenac—Vision blurred—Ifosfamide—testicular cancer	3.98e-05	0.0103	CcSEcCtD
Nepafenac—Dry eye—Epirubicin—testicular cancer	3.95e-05	0.0102	CcSEcCtD
Nepafenac—Eye disorder—Cisplatin—testicular cancer	3.91e-05	0.0101	CcSEcCtD
Nepafenac—Hypersensitivity—Chlorambucil—testicular cancer	3.84e-05	0.00992	CcSEcCtD
Nepafenac—Diabetes mellitus—Methotrexate—testicular cancer	3.81e-05	0.00986	CcSEcCtD
Nepafenac—Immune system disorder—Cisplatin—testicular cancer	3.78e-05	0.00977	CcSEcCtD
Nepafenac—Pruritus—Chlorambucil—testicular cancer	3.68e-05	0.00953	CcSEcCtD
Nepafenac—Dry eye—Doxorubicin—testicular cancer	3.65e-05	0.00945	CcSEcCtD
Nepafenac—Hypertension—Ifosfamide—testicular cancer	3.64e-05	0.00943	CcSEcCtD
Nepafenac—Eye disorder—Etoposide—testicular cancer	3.58e-05	0.00926	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	3.57e-05	0.00923	CcSEcCtD
Nepafenac—Diabetes mellitus—Epirubicin—testicular cancer	3.57e-05	0.00923	CcSEcCtD
Nepafenac—Hypersensitivity—Vinblastine—testicular cancer	3.52e-05	0.00909	CcSEcCtD
Nepafenac—Angiopathy—Etoposide—testicular cancer	3.47e-05	0.00899	CcSEcCtD
Nepafenac—Immune system disorder—Etoposide—testicular cancer	3.46e-05	0.00895	CcSEcCtD
Nepafenac—Eye pain—Epirubicin—testicular cancer	3.44e-05	0.00889	CcSEcCtD
Nepafenac—Vision blurred—Cisplatin—testicular cancer	3.43e-05	0.00887	CcSEcCtD
Nepafenac—Nervous system disorder—Ifosfamide—testicular cancer	3.38e-05	0.00874	CcSEcCtD
Nepafenac—Skin disorder—Ifosfamide—testicular cancer	3.35e-05	0.00865	CcSEcCtD
Nepafenac—Vomiting—Chlorambucil—testicular cancer	3.31e-05	0.00856	CcSEcCtD
Nepafenac—Diabetes mellitus—Doxorubicin—testicular cancer	3.3e-05	0.00854	CcSEcCtD
Nepafenac—Eye pain—Doxorubicin—testicular cancer	3.18e-05	0.00823	CcSEcCtD
Nepafenac—Dizziness—Vinblastine—testicular cancer	3.16e-05	0.00816	CcSEcCtD
Nepafenac—Nausea—Chlorambucil—testicular cancer	3.09e-05	0.008	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	3.08e-05	0.00796	CcSEcCtD
Nepafenac—Vomiting—Vinblastine—testicular cancer	3.03e-05	0.00785	CcSEcCtD
Nepafenac—Headache—Vinblastine—testicular cancer	2.99e-05	0.00773	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Ifosfamide—testicular cancer	2.97e-05	0.00769	CcSEcCtD
Nepafenac—Hypersensitivity—Bleomycin—testicular cancer	2.97e-05	0.00768	CcSEcCtD
Nepafenac—Nervous system disorder—Cisplatin—testicular cancer	2.91e-05	0.00753	CcSEcCtD
Nepafenac—Skin disorder—Cisplatin—testicular cancer	2.88e-05	0.00746	CcSEcCtD
Nepafenac—Hypertension—Etoposide—testicular cancer	2.88e-05	0.00744	CcSEcCtD
Nepafenac—Pruritus—Bleomycin—testicular cancer	2.85e-05	0.00738	CcSEcCtD
Nepafenac—Nausea—Vinblastine—testicular cancer	2.83e-05	0.00733	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	2.82e-05	0.00729	CcSEcCtD
Nepafenac—Hypersensitivity—Dactinomycin—testicular cancer	2.77e-05	0.00716	CcSEcCtD
Nepafenac—Skin disorder—Etoposide—testicular cancer	2.64e-05	0.00684	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Cisplatin—testicular cancer	2.56e-05	0.00663	CcSEcCtD
Nepafenac—Vomiting—Bleomycin—testicular cancer	2.56e-05	0.00663	CcSEcCtD
Nepafenac—Hypersensitivity—Ifosfamide—testicular cancer	2.54e-05	0.00656	CcSEcCtD
Nepafenac—Pruritus—Ifosfamide—testicular cancer	2.44e-05	0.0063	CcSEcCtD
Nepafenac—Nausea—Bleomycin—testicular cancer	2.39e-05	0.00619	CcSEcCtD
Nepafenac—Vomiting—Dactinomycin—testicular cancer	2.39e-05	0.00618	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Etoposide—testicular cancer	2.35e-05	0.00608	CcSEcCtD
Nepafenac—Dizziness—Ifosfamide—testicular cancer	2.28e-05	0.00589	CcSEcCtD
Nepafenac—Sinusitis—Epirubicin—testicular cancer	2.24e-05	0.0058	CcSEcCtD
Nepafenac—Nausea—Dactinomycin—testicular cancer	2.23e-05	0.00578	CcSEcCtD
Nepafenac—Vomiting—Ifosfamide—testicular cancer	2.19e-05	0.00567	CcSEcCtD
Nepafenac—Hypersensitivity—Cisplatin—testicular cancer	2.19e-05	0.00566	CcSEcCtD
Nepafenac—Eye disorder—Methotrexate—testicular cancer	2.14e-05	0.00554	CcSEcCtD
Nepafenac—Angiopathy—Methotrexate—testicular cancer	2.08e-05	0.00538	CcSEcCtD
Nepafenac—Sinusitis—Doxorubicin—testicular cancer	2.08e-05	0.00537	CcSEcCtD
Nepafenac—Immune system disorder—Methotrexate—testicular cancer	2.07e-05	0.00536	CcSEcCtD
Nepafenac—Nausea—Ifosfamide—testicular cancer	2.05e-05	0.00529	CcSEcCtD
Nepafenac—Eye disorder—Epirubicin—testicular cancer	2.01e-05	0.00519	CcSEcCtD
Nepafenac—Hypersensitivity—Etoposide—testicular cancer	2e-05	0.00518	CcSEcCtD
Nepafenac—Angiopathy—Epirubicin—testicular cancer	1.95e-05	0.00504	CcSEcCtD
Nepafenac—Immune system disorder—Epirubicin—testicular cancer	1.94e-05	0.00502	CcSEcCtD
Nepafenac—Pruritus—Etoposide—testicular cancer	1.92e-05	0.00498	CcSEcCtD
Nepafenac—Vomiting—Cisplatin—testicular cancer	1.89e-05	0.00488	CcSEcCtD
Nepafenac—Vision blurred—Methotrexate—testicular cancer	1.88e-05	0.00487	CcSEcCtD
Nepafenac—Eye disorder—Doxorubicin—testicular cancer	1.86e-05	0.0048	CcSEcCtD
Nepafenac—Angiopathy—Doxorubicin—testicular cancer	1.8e-05	0.00466	CcSEcCtD
Nepafenac—Dizziness—Etoposide—testicular cancer	1.8e-05	0.00465	CcSEcCtD
Nepafenac—Immune system disorder—Doxorubicin—testicular cancer	1.79e-05	0.00464	CcSEcCtD
Nepafenac—Nausea—Cisplatin—testicular cancer	1.76e-05	0.00456	CcSEcCtD
Nepafenac—Vision blurred—Epirubicin—testicular cancer	1.76e-05	0.00456	CcSEcCtD
Nepafenac—Vomiting—Etoposide—testicular cancer	1.73e-05	0.00447	CcSEcCtD
Nepafenac—Headache—Etoposide—testicular cancer	1.7e-05	0.00441	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	1.69e-05	0.00437	CcSEcCtD
Nepafenac—Vision blurred—Doxorubicin—testicular cancer	1.63e-05	0.00421	CcSEcCtD
Nepafenac—Nausea—Etoposide—testicular cancer	1.62e-05	0.00418	CcSEcCtD
Nepafenac—Hypertension—Epirubicin—testicular cancer	1.61e-05	0.00417	CcSEcCtD
Nepafenac—Nervous system disorder—Methotrexate—testicular cancer	1.6e-05	0.00413	CcSEcCtD
Nepafenac—Skin disorder—Methotrexate—testicular cancer	1.58e-05	0.00409	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	1.58e-05	0.00409	CcSEcCtD
Nepafenac—Dry mouth—Epirubicin—testicular cancer	1.56e-05	0.00402	CcSEcCtD
Nepafenac—Nervous system disorder—Epirubicin—testicular cancer	1.5e-05	0.00387	CcSEcCtD
Nepafenac—Hypertension—Doxorubicin—testicular cancer	1.49e-05	0.00386	CcSEcCtD
Nepafenac—Skin disorder—Epirubicin—testicular cancer	1.48e-05	0.00383	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	1.46e-05	0.00378	CcSEcCtD
Nepafenac—Dry mouth—Doxorubicin—testicular cancer	1.44e-05	0.00372	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Methotrexate—testicular cancer	1.41e-05	0.00364	CcSEcCtD
Nepafenac—Nervous system disorder—Doxorubicin—testicular cancer	1.38e-05	0.00358	CcSEcCtD
Nepafenac—Skin disorder—Doxorubicin—testicular cancer	1.37e-05	0.00355	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Epirubicin—testicular cancer	1.32e-05	0.00341	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Doxorubicin—testicular cancer	1.22e-05	0.00315	CcSEcCtD
Nepafenac—Hypersensitivity—Methotrexate—testicular cancer	1.2e-05	0.00311	CcSEcCtD
Nepafenac—Pruritus—Methotrexate—testicular cancer	1.15e-05	0.00298	CcSEcCtD
Nepafenac—Hypersensitivity—Epirubicin—testicular cancer	1.12e-05	0.00291	CcSEcCtD
Nepafenac—Pruritus—Epirubicin—testicular cancer	1.08e-05	0.00279	CcSEcCtD
Nepafenac—Dizziness—Methotrexate—testicular cancer	1.08e-05	0.00279	CcSEcCtD
Nepafenac—Hypersensitivity—Doxorubicin—testicular cancer	1.04e-05	0.00269	CcSEcCtD
Nepafenac—Vomiting—Methotrexate—testicular cancer	1.04e-05	0.00268	CcSEcCtD
Nepafenac—Headache—Methotrexate—testicular cancer	1.02e-05	0.00264	CcSEcCtD
Nepafenac—Dizziness—Epirubicin—testicular cancer	1.01e-05	0.00261	CcSEcCtD
Nepafenac—Pruritus—Doxorubicin—testicular cancer	9.98e-06	0.00258	CcSEcCtD
Nepafenac—Vomiting—Epirubicin—testicular cancer	9.7e-06	0.00251	CcSEcCtD
Nepafenac—Nausea—Methotrexate—testicular cancer	9.68e-06	0.0025	CcSEcCtD
Nepafenac—Headache—Epirubicin—testicular cancer	9.55e-06	0.00247	CcSEcCtD
Nepafenac—Dizziness—Doxorubicin—testicular cancer	9.33e-06	0.00241	CcSEcCtD
Nepafenac—Nausea—Epirubicin—testicular cancer	9.06e-06	0.00234	CcSEcCtD
Nepafenac—Vomiting—Doxorubicin—testicular cancer	8.97e-06	0.00232	CcSEcCtD
Nepafenac—Headache—Doxorubicin—testicular cancer	8.84e-06	0.00229	CcSEcCtD
Nepafenac—Nausea—Doxorubicin—testicular cancer	8.38e-06	0.00217	CcSEcCtD
